Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance

Cytokinetics IncTrade
Roundhill Innov-100 0DTE Covered Call Strat ETFTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.63B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.77. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.

CYTKQDTE
Market Cap
$10.63B
Sector
TechnologyIncome / Options Overlay
52-Week High
$87.26$36.60
52-Week Low
$34.31$26.85
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.

Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE trades at $29.69 with a 1.19% daily gain, but technical indicators signal bearish momentum with resistance at $30. The ETF faces fundamental concerns as its high distribution yield appears funded by return of capital rather than organic earnings, potentially eroding NAV over time. Recent news highlights growing skepticism about the sustainability of its 24% yield strategy.

Outlook remains cautious due to structural yield concerns and NAV erosion risks. While weekly distributions attract income seekers, the fund's reliance on return of capital poses significant long-term value destruction risks. Investors should weigh high current income against potential principal erosion in volatile market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.

Read more on QDTE